Abbott Receives US Authorization For First 'Virtually Guided' At-Home Rapid Test
Abbott plans to deliver 30 million BinaxNOW prescription, at-home rapid tests in the first quarter of 2021; 90 million more in the second quarter.
You may also be interested in...
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
A panel of experts, including the CEO of Roche Diagnostics, discussed how the pandemic will lead to a ”reimagining” of diagnostics, expanding access for testing with at-home testing and virtual care.
In what could be a game-changer in the fight against the coronavirus, Lucira Health has received the first-ever emergency use authorization from the US FDA for an at-home prescription diagnostic test kit for detecting SARS-CoV-2.